Overcoming TRAIL resistance in ovarian carcinoma

Gynecologic Oncology
Kerri S BevisJ Michael Straughn

Abstract

Ovarian cancer, the deadliest of the gynecologic malignancies, poses a therapeutic challenge because of the 70% recurrence rate among patients treated with taxane/platinum-based chemotherapy. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer therapy due to its ability to selectively induce apoptosis in cancer cells with little toxicity to normal cells. Despite initially promising results from early TRAIL studies in ovarian cancer, reports of significant TRAIL resistance soon followed. The current study reviews strategies to overcome TRAIL resistance in ovarian cancer. PubMed was searched for published literature in English using key words "TRAIL," "ovarian," "death receptor" and "resistance". The references of identified articles were then searched for further related literature. A number of mechanisms underlying TRAIL resistance have been proposed, including absence of death receptor expression and genetic alterations, leading to silencing of the downstream effects of ligand binding. Numerous strategies to overcome these mechanisms have been investigated, including combination treatment with cytotoxic chemotherapy, retinoids, proteasome inhibitors, demethylating agents, Akt inhibitors a...Continue Reading

References

Jun 1, 1995·Cancer Metastasis Reviews·J M Lee, A Bernstein
May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Apr 1, 1996·Current Opinion in Immunology·B A Osborne
Nov 28, 1996·Nature·J KitsonS N Farrow
Feb 7, 1997·Cell·S Nagata
Apr 4, 1997·Science·G PanV M Dixit
Jul 25, 1997·The Journal of Biological Chemistry·P SchneiderJ Tschopp
Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Apr 16, 1998·Trends in Biochemical Sciences·J H Naismith, S R Sprang
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
May 11, 2002·Nature Reviews. Cancer·Frederik H Igney, Peter H Krammer
Aug 3, 2002·Nature Reviews. Cancer·Karen H Vousden, Xin Lu
Mar 26, 2003·Cell Death and Differentiation·H N LeBlanc, A Ashkenazi
Mar 26, 2003·Cell Death and Differentiation·Lars E French, Jürg Tschopp
Oct 18, 2003·Seminars in Immunology·Bryan C BarnhartMarcus E Peter
Oct 31, 2003·Essays in Biochemistry·Harald Wajant
Nov 7, 2003·Journal of Clinical Immunology·Anjana Bhardwaj, Bharat B Aggarwal
Feb 26, 2004·Cell·Eugene E Varfolomeev, Avi Ashkenazi
Mar 5, 2004·International Journal of Cancer. Journal International Du Cancer·Narayan ShivapurkarAdi F Gazdar
Apr 20, 2004·Toxicology Letters·Sten Orrenius
Nov 13, 2004·Cell Research·Fiona C Kimberley, Gavin R Screaton
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas J Herzog
Dec 9, 2004·Biochimica Et Biophysica Acta·Simone Fulda, Klaus-Michael Debatin
Oct 11, 2005·Apoptosis : an International Journal on Programmed Cell Death·T AbdollahiG Litwack
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric K Rowinsky
May 10, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P LiuP Hou
Jan 26, 2007·Apoptosis : an International Journal on Programmed Cell Death·Ernestina SaulleUgo Testa
Feb 13, 2007·Gynecologic Oncology·Eleonora PetrucciUgo Testa
Apr 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherRoger B Cohen
May 31, 2007·International Journal of Cancer. Journal International Du Cancer·Denis LaneAlain Piché
Sep 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·D LaneA Piché
Nov 22, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hong Luan MaoChunxi Liu
Feb 8, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·F Anthony GrecoJerry Klein

❮ Previous
Next ❯

Citations

Jan 15, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Letícia da Conceição BragaAgnaldo Lopes da Silva Filho
Nov 6, 2013·Archives of Gynecology and Obstetrics·Letícia da Conceição BragaAgnaldo Lopes da Silva Filho
May 5, 2012·Gynecologic Oncology·Letícia da Conceição BragaAgnaldo Lopes da Silva-Filho
May 11, 2013·Journal of Bioscience and Bioengineering·Chia-Che ChangTsing-Fen Ho
Aug 23, 2011·American Journal of Obstetrics and Gynecology·Liang-Cheng LiBellur S Prabhakar
Feb 22, 2012·Clinical Obstetrics and Gynecology·Angela J ZiebarthRonald D Alvarez
Jan 5, 2021·Journal of Experimental & Clinical Cancer Research : CR·Andrea RizzoMarina Bagnoli
Nov 22, 2013·Molecular Pharmaceutics·Laura GattiPaola Perego

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis